News and Announcements
COMMENTARY
Psychological safety in T-cell-redirecting immunotherapy
Show Less
1 Department of Psychosomatic Medicine and Psychotherapy, University Hospital Würzburg, Würzburg,
Germany
HPR, 026250130 https://doi.org/10.36922/HPR026250130
Received: 15 June 2026 | Revised: 3 July 2026 | Accepted: 7 July 2026 | Published online: 13 July 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Funding
Anna Fleischer was supported by the Clinician Scientist College TWINSIGHT at the Medical Faculty of the University of Würzburg, which is funded by the Else Kröner-Fresenius Foundation.
Conflict of interest
The author received honoraria from GSK, BMS, and Janssen outside the submitted work.
References
- Dhawale TM, Salas MQ, D'Souza A, et al. Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy. Cancer. 2023;129(3):441-449. doi: 10.1002/cncr.34557
- Riba MB, Donovan KA, Andersen B, et al. Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(10):1229-1249. doi: 10.6004/jnccn.2019.0048
- Leventhal H, Phillips LA, Burns E. The Common-Sense Model of Self-Regulation (CSM): a dynamic framework for understanding illness self-management. J Behav Med. 2016;39(6):935-946. doi: 10.1007/s10865-016-9782-2
- Adair KC, Heath A, Frye MA, et al. The Psychological Safety Scale of the Safety, Communication, Operational, Reliability, and Engagement (SCORE) Survey: a brief, diagnostic, and actionable metric for the ability to speak up in healthcare settings. J Patient Saf. 2022;18(6):513-520. doi: 10.1097/PTS.0000000000001048
- Khatsuria F, McMullan C, Aiyegbusi OL, et al. Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies. Lancet Oncol. 2024;25(10):e476-e488. doi: 10.1016/S1470-2045(24)00256-0